BIOTECH TARGET N V purchased ~$11M in Esperion Therapeutics, Inc. stock
Esperion Therapeutics, Inc. (ESPR) · Data via SEC EDGAR Form 4
Price Performance · 10 days before → 90 days after trade
▲ = insider buy date
90-day return
-28.7%vs SPY +6.5%
Trade Details · Public SEC Filing
Insider
BIOTECH TARGET N V
Role
—
Transaction
Open-Market Purchase
Approx. Value
~$11M
Trade Date
May 5, 2021
Company
Esperion Therapeutics, Inc.
Ticker
ESPRSource
SEC EDGAR Form 4
Why This Trade Stands Out
Strong conviction signal
Scored above average across multiple factors. Roughly 15% of insider trades qualify as Strong.
~$11M purchase
Trades over $1M are rare. When insiders put this much of their own money on the line, they tend to have high conviction in their company's direction.
-28.7% in 90 days (S&P 500: +6.5%)
This trade underperformed the S&P 500 by 35.1 percentage points. Not every insider trade wins. We track all of them so you can focus on the insiders with the best records.
How good is BIOTECH TARGET N V at picking stocks?
Full track record: win rate, average return, and performance vs S&P 500
On May 5, 2021, BIOTECH TARGET N V — a corporate insider at Esperion Therapeutics, Inc. — filed a Form 4 with the SEC disclosing an open-market purchase of approximately ~$11M in Esperion Therapeutics, Inc. (ESPR) stock.
Under Section 16(a) of the Securities Exchange Act of 1934, corporate insiders must report all open-market stock transactions to the SEC within two business days. These filings — known as Form 4s — are publicly available on the SEC's EDGAR database. VeritySignals filters and scores the full Form 4 stream to surface high-conviction signals like this one.
In the 90 days following this trade, ESPR returned -28.7% versus +6.5% for the S&P 500 over the same period.
VeritySignals Conviction Analysis
Full Conviction Analysis
Sign up free to see signal strength details, or upgrade for the full 15-factor breakdown.
Get notified the next time BIOTECH TARGET N V trades
Free alerts · No credit card · Instant notification
All data sourced from publicly available SEC Form 4 filings via EDGAR · Not financial advice · Past performance does not guarantee future results.
At a Glance
More ESPR Insider Activity
Koenig Sheldon L.
Jun 17, 2026
~$481K
STRONG
Koenig Sheldon L.
Mar 17, 2026
~$205K
STRONG
Koenig Sheldon L.
Mar 17, 2026
~$205K
STRONG
Koenig Sheldon L.
Dec 17, 2025
~$456K
STRONG
How to Read Insider Trades
What is this?
When company executives buy or sell their own stock, they must report it to the SEC within 2 days. These public filings reveal what the people who know the company best are doing with their own money.
Why does it matter?
Insiders can sell for many reasons (taxes, diversification, expenses), but they generally only buy for one: they think the stock is going up. That's why insider purchases are more predictive than sales.
What makes a trade "strong"?
We score trades on 15+ factors: the insider's role (CEO > director), trade size relative to their salary, whether other insiders also bought (clusters), and historical accuracy of the insider.
Never miss a signal
Get notified when high-conviction insiders buy. Free account, no credit card.
Sign up free